Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 51.92 USD 1.47% Market Closed
Market Cap: 9.8B USD

EV/EBIT
Enterprise Value to EBIT

-68
Current
-50.8
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-68
=
Enterprise Value
11.3B USD
/
EBIT
-166.8m USD
EBIT Growth EV/EBIT to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average EV/EBIT: 19.6
Negative Multiple: -68
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 698.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -351.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-130.9
2-Years Forward
EV/EBIT
127.7
3-Years Forward
EV/EBIT
51.9